Komo Plant-Based Foods Inc.

Komo Announces 10:1 Consolidation

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ( the “Company”, “Komo”), a premium plant‐based food company, announces that, effective at the opening of trading on January 30, 2023 (the "Effective Date") the common shares of the Company (the "Common Shares") will commence trading on the Canadian Securities Exchange on a consolidated basis, with one (1) post-consolidated Common Share outstanding for every ten (10) pre-consolidated Common Shares (the "Consolidation"). The Company's name and trading symbol will remain unchanged.

As a result of the Consolidation, on the Effective Date, a total of approximately 9,709,102 Common Shares will be issued and outstanding, subject to adjustments for rounding, with approximately 7,276,992 Common Shares reserved for issuance. No fractional Common Shares will be issued, and any post-consolidated fraction of a Common Share will be rounded to the nearest whole number of Common Shares. The name of the Company has not been changed, and the trading symbol remains as "YUM". A new CUSIP number has been issued for the post-consolidated Common Shares, being 50046B205.

The exercise or conversion price and the number of Common Shares issuable under any of the Company's outstanding convertible instruments will be proportionately adjusted upon the effectiveness of the Consolidation. In accordance with the Company’s Articles, the Consolidation does not require shareholder approval.

Shareholders of record as of the Effective Date who hold Common Shares represented by a DRS (direct registration system) statement will receive an updated DRS statement from the transfer agent for the Company, Endeavor Trust Corporation, representing Common Shares on a post-Consolidation basis.

The Consolidation is subject to the acceptance of the Canadian Securities Exchange.

About Komo

Komo Plant Based Foods is a premium plant-based food company that develops, manufactures and sells a variety of plant-based frozen meals that are always hearty, satisfying and made with wholesome ingredients. At Komo, the company's mission is to help make plant-based meals a staple on every dinner table by sharing the company's love for feel-good food that connects the people to the planet. The company believes plant-based eating is the future and that "Change can start with a single bite." The company's experienced plant-based innovation and development team recreates vegan versions of traditionally cheesy and meaty classics, with 100 per cent plants. Komo's products are sold direct-to-consumer through the company's e-commerce website, and a distribution network of on-line and brick and mortar grocery, convenience and natural retailer channels. The company's operating subsidiary, Komo Comfort Foods, launched in 2021 with the company's flagship products: plant-based lasagna, shepherd's pie and chickenless pot pie, and Komo Plant-Based Meal Helpers -- versatile meal starters to allow the creation of many dishes at home. Komo's newest product is Mac & Greens. All of the company's products are 100-per-cent plant-based, made with wholesome ingredients, free from preservatives and frozen for freshness. Freezing products is a natural and effective way of keeping food products for longer without having to use any preservatives. Komo's meals have an 18-month frozen shelf life.

Learn more at: www.komocomfortfoods.com and follow on Instagram: @komocomfortfoods For further information, please contact:

William White, President & CEO, Komo Plant Based Foods Inc.

will@komoeats.com

+1 (236) 8000‐YUM / (236) 800‐0986

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward‐Looking Statements

Certain statements contained in this press release constitute forward‐looking information. These statements relate to future events or Komo's future performance. The use of any of the words and similar expressions and statements relating to matters that are not historical facts are intended to identify forward‐looking information and are based on Komo management's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, Komo's ability to retain key personnel, its projected revenues, its projected expenses, its ability to raise capital, and its expectation as to the continued increase in the number of retailers and consumers of its products constitute forward‐ looking information. Actual results and developments may differ materially from those contemplated by forward‐looking information. Readers are cautioned not to place undue reliance on forward‐looking information. The statements made in this press release are made as of the date hereof. Komo disclaims any intention or obligation to publicly update or revise any forward‐looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

Source

Click here to connect with Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0), to receive an Investor Presentation

YUM:CC
The Conversation (0)
Komo Expands Frozen Meal Line to Fortinos Stores in Toronto

Komo Expands Frozen Meal Line to Fortinos Stores in Toronto

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ( the "Company", "Komo"), Komo Plant Based Foods Inc. Expands Frozen Meal Line to All 9 SKUs in Fortinos Stores in Toronto.

Komo Plant Based Foods Inc., a premium, fast-growing plant-based food products manufacturer, is thrilled to announce the expansion of their frozen meal line to all 9 SKUs in Fortinos stores across the Greater Toronto Area (GTA). The partnership will make Komo's delicious and nutritious plant-based meals more accessible to families in Toronto, helping to make healthy meal planning more convenient and affordable.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2

Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOD) (FSE: 9HB) ("Komo"), a premium plant-based food company, is pleased to announce it achieved record revenues for its second financial quarter ended January 31, 2023. Komo generated revenues of $466,197 in the quarter, which is a 160% increase from the first quarter revenues of $179,467. The increase is attributed to Komo's recent growth across Canada with its retail distribution through Loblaws, Loblaws banner stores, Sobeys, Whole Foods and key natural accounts. This also represents a 181% increase from last year's Q2 report which had revenue of $166,052. Komo reported a gross profit margin of 39% in Q1 of 2023.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Expands Across Canada with Whole Foods Market

Komo Expands Across Canada with Whole Foods Market

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) (the "Company", "Komo"), a premium plant‐based food company, reports planned expansion across Canada with Whole Foods Market.

Komo Plant Based Foods Inc., a fast growing plant-based food products manufacturer, announces today that it will be expanding its presence in Canada through additional distribution at Whole Foods Markets. Komo's line of frozen meals and meal helpers will now be available in all 14 Whole Foods Market locations in Canada, with the newly expanded listings to be on shelves by May of 2023.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Doubles Retail Distribution to 840 Stores

Komo Doubles Retail Distribution to 840 Stores

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) (the "Company", "Komo"), a premium plant‐based food company, reports significant growth in the number of retail stores carrying Komo products with an increase of over 100% in 3 months.

Komo Plant Based Foods Inc., a fast-growing plant-based food products manufacturer, announces a 100% increase in retail distribution since November of 2022, now available in 840 grocery retail locations across Canada. This impressive growth includes Loblaw's and Loblaws' banner stores and the addition of 50 new retail stores in January 2023, including Georgia Main Group (IGA West and Fresh St. Market), Sobey's West, Safeway and Freson Brothers locations in western Canada, and key natural accounts such as Boites à Grain in Quebec.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Reports Q1 Financial Results

Komo Reports Q1 Financial Results

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ( the "Company", "Komo"), a premium plant‐based food company, reports financial results for the quarterly period ended October 31, 2022.

FINANCIAL RESULTS

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Young female researcher working in a lab.

Radiopharmaceuticals Take Investors to the Forefront of Precision Oncology

Radiopharmaceuticals are emerging as one of the most promising innovations in modern medicine, particularly in precision oncology, and if recent billion-dollar investment deals are any indication, the potential for growth can be significant. Investors eyeing exposure to this emerging technology would benefit from a deeper understanding of the technology, its strategic applications and investment opportunities.

A groundbreaking technology in the field of oncology, radiopharmaceuticals combine radioactive substances with targeted molecules to revolutionise cancer detection and treatment. These innovative compounds are gaining significant attention due to their ability to deliver precise and targeted cancer therapies, minimising damage to healthy tissues while maximising therapeutic efficacy.

At their core, radiopharmaceuticals leverage the unique properties of radioactive isotopes, pairing them with molecules that have a high affinity for cancer cells. This combination allows for both diagnostic imaging and therapeutic applications, offering a level of precision previously unattainable in traditional cancer treatments.

Keep reading...Show less
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology .

About the Study

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Howard Chang , M.D., Ph.D.,   Joins as Senior Vice President of Research and Chief Scientific Officer

Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Top 5 Life Science ETFs in 2024

Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

There are many choices when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top life science ETFs by year-on-year performance.

Keep reading...Show less
Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.
Keep reading...Show less

Latest Press Releases

Related News

×